Leavell Investment Management Inc. Increases Position in CRISPR Therapeutics AG $CRSP

Leavell Investment Management Inc. boosted its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 77.8% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 17,777 shares of the company’s stock after acquiring an additional 7,777 shares during the period. Leavell Investment Management Inc.’s holdings in CRISPR Therapeutics were worth $865,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. SVB Wealth LLC acquired a new stake in shares of CRISPR Therapeutics during the first quarter worth $25,000. Costello Asset Management INC purchased a new position in CRISPR Therapeutics during the first quarter worth about $27,000. IFP Advisors Inc boosted its stake in CRISPR Therapeutics by 24.6% in the 2nd quarter. IFP Advisors Inc now owns 916 shares of the company’s stock worth $45,000 after buying an additional 181 shares during the last quarter. Quantbot Technologies LP grew its holdings in CRISPR Therapeutics by 272.4% in the 1st quarter. Quantbot Technologies LP now owns 1,337 shares of the company’s stock valued at $45,000 after buying an additional 978 shares during the period. Finally, Caitong International Asset Management Co. Ltd grew its holdings in CRISPR Therapeutics by 1,923.1% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 1,841 shares of the company’s stock valued at $90,000 after buying an additional 1,750 shares during the period. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insiders Place Their Bets

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,076 shares of the business’s stock in a transaction on Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total value of $71,661.60. Following the transaction, the general counsel owned 83,402 shares in the company, valued at $5,554,573.20. The trade was a 1.27% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Samarth Kulkarni sold 50,895 shares of the firm’s stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $67.91, for a total value of $3,456,279.45. Following the sale, the chief executive officer owned 254,201 shares of the company’s stock, valued at $17,262,789.91. This represents a 16.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 56,213 shares of company stock worth $3,810,458. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP opened at $67.61 on Monday. The business’s 50-day moving average is $61.62 and its two-hundred day moving average is $51.52. The firm has a market capitalization of $6.15 billion, a PE ratio of -12.45 and a beta of 1.84. CRISPR Therapeutics AG has a 12 month low of $30.04 and a 12 month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.18. The business had revenue of $0.89 million during the quarter, compared to analyst estimates of $6.44 million. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%.The company’s revenue for the quarter was up 72.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.49) earnings per share. Equities analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Analyst Ratings Changes

Several research firms recently issued reports on CRSP. Chardan Capital reissued a “buy” rating and issued a $82.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, August 5th. JPMorgan Chase & Co. began coverage on shares of CRISPR Therapeutics in a report on Thursday, September 18th. They issued an “overweight” rating and a $70.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Friday. Bank of America increased their target price on CRISPR Therapeutics from $78.00 to $93.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Finally, Wells Fargo & Company set a $75.00 price target on CRISPR Therapeutics in a research report on Monday, October 13th. Ten analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $72.59.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.